Valuation: Aspen Pharmacare Holdings Limited

Market Cap 72.99B 4.49B 3.92B 3.69B 3.36B 6.3B 430B 6.31B 44.19B 17.03B 219B 16.88B 16.5B 708B P/E 2026
26.3x
P/E 2027 * 15x
Enterprise Value 85.87B 5.29B 4.61B 4.34B 3.95B 7.41B 506B 7.42B 51.99B 20.04B 258B 19.86B 19.42B 832B EV / Sales 2026
-
EV / Sales 2027 * 1.91x
Free-Float
58.39%
Yield 2026
1.48%
Yield 2027 * 1.5%
1 week+4.22%
Current month+4.22%
1 month+10.19%
3 months+8.81%
6 months+32.06%
Current year+49.14%
1 week 8.1
Extreme 8.1
8.75
1 month 7.6
Extreme 7.6
8.75
3 years 4.46
Extreme 4.46
12.7
5 years 4.46
Extreme 4.46
15.6
10 years 3.75
Extreme 3.747
22.52
Manager TitleAgeSince
Chief Executive Officer 62 1996-12-31
Director of Finance/CFO 61 2008-12-31
Chief Operating Officer 63 1998-12-31
Director TitleAgeSince
Director/Board Member 62 1998-12-31
Director/Board Member 65 1998-12-31
Chairman 58 2015-12-06
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%+4.22%+78.72%+2.37% 4.49B
-1.20%+0.62%+12.31%+63.06% 46.81B
-1.02%-1.29%+36.59%+104.00% 37.1B
+0.11%+5.76%+12.22%+95.15% 12.09B
-0.14%+2.45%-10.25%+16.71% 11.69B
0.00%-0.95%+19.27%+142.99% 9.03B
-0.85%+1.03%+27.52%+39.02% 7.45B
+0.47%+3.78%+21.98%+206.60% 7.22B
-0.06%+2.20%+39.67%-16.79% 7.13B
+3.26%+3.77%-40.07%+13.57% 5.19B
Average +0.06%+1.99%+19.80%+66.67% 15.97B
Weighted average by Cap. -0.56%+1.03%+19.76%+75.51%

Financials

2026 2027 *
Net sales 37.62B 2.32B 2.02B 1.9B 1.73B 3.25B 222B 3.25B 22.78B 8.78B 113B 8.7B 8.51B 365B 37.04B 2.28B 1.99B 1.87B 1.71B 3.2B 218B 3.2B 22.43B 8.64B 111B 8.57B 8.38B 359B
Net income 4.8B 295M 258M 243M 221M 414M 28.3B 415M 2.9B 1.12B 14.42B 1.11B 1.08B 46.52B 4.77B 294M 256M 241M 220M 412M 28.13B 412M 2.89B 1.11B 14.33B 1.1B 1.08B 46.24B
Net Debt 12.88B 793M 691M 651M 593M 1.11B 75.95B 1.11B 7.8B 3.01B 38.69B 2.98B 2.91B 125B -2.41B -149M -130M -122M -111M -208M -14.24B -209M -1.46B -563M -7.25B -558M -546M -23.4B
Logo Aspen Pharmacare Holdings Limited
Aspen Pharmacare Holdings Limited is the African leading pharmaceutical group. The group's products are primarily for the treatment of asthma, HIV, bacterial infections, gastro-intestinal, respiratory and inflammatory diseases. Net sales break down by family of products as follows: - pharmaceuticals (68.4%): anaesthetics products, thrombosis products, cytotoxic products, etc.; - other (31.6%): infant nutrition products and consumer products. At the end of June 2024, the group had 24 production sites worldwide.
Employees
-
Date Price Change
26-09-22 8.550 -1.16%
26-09-21 €8.650 +6.13%
26-09-18 €8.150 0.00%
26-09-17 €8.150 -0.61%
26-09-16 €8.200 +0.61%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
164.38ZAR
Average target price
172.67ZAR
Spread / Average Target
+5.04%

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!